US Bancorp
PCVX icon

US Bancorp’s Vaxcyte PCVX Stock Holding History

US Bancorp’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.3K Sell
1,502
-140
-9% -$7.6K ﹤0.01% 2525
2026
Q1 		$95.4K Buy
1,642
+168
+11% +$9.12K ﹤0.01% 2410
2025
Q4 		$68K Buy
1,474
+288
+24% +$12.9K ﹤0.01% 2560
2025
Q3 		$42.7K Sell
1,186
-1,208
-50% -$40K ﹤0.01% 2748
2025
Q2 		$77.8K Sell
2,394
-2,950
-55% -$96.7K ﹤0.01% 2564
2025
Q1 		$202K Buy
5,344
+357
+7% +$28.5K ﹤0.01% 1991
2024
Q4 		$408K Sell
4,987
-2,055
-29% -$204K ﹤0.01% 1607
2024
Q3 		$805K Sell
7,042
-1,958
-22% -$176K ﹤0.01% 1243
2024
Q2 		$680K Buy
9,000
+1,505
+20% +$102K ﹤0.01% 1303
2024
Q1 		$512K Sell
7,495
-9,035
-55% -$626K ﹤0.01% 1491
2023
Q4 		$1.04M Sell
16,530
-3,652
-18% -$190K ﹤0.01% 1095
2023
Q3 		$1.03M Buy
20,182
+19,484
+2,791% +$961K ﹤0.01% 1039
2023
Q2 		$34.9K Sell
698
-156
-18% -$7.39K ﹤0.01% 2699
2023
Q1 		$32K Sell
854
-71
-8% -$3.01K ﹤0.01% 2744
2022
Q4 		$44.4K Buy
925
+815
+741% +$32K ﹤0.01% 2602
2022
Q3 		$3K Buy
+110
New +$2.79K ﹤0.01% 3749

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

US Bancorp's PCVX Position: Q2 2026 in Review

US Bancorp reduced its Vaxcyte (PCVX) stake by 8.5% in Q2 2026, selling an estimated $7.6K and leaving 1,502 shares worth $87.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2525.

US Bancorp first reported a position in PCVX in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.04M in Q4 2023. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • US Bancorp held 1,502 shares of Vaxcyte worth $87.3K as of Q2 2026.
  • US Bancorp sold 140 Vaxcyte shares in Q2 2026, an estimated $7.6K.
  • Vaxcyte made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2525 holding.
  • US Bancorp first reported a position in Vaxcyte in Q3 2022 and has held it in 16 quarters since.
  • US Bancorp's Vaxcyte position peaked at $1.04M in Q4 2023.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.